Overcoming Cancers Resistant to HER-2 Antibodies provides general
updated information on the resistance of various human cancers to
anti-HER2 therapeutic antibodies. The book also discusses the
description of various sensitizing agents that can reverse
resistance when used in combination with anti-HER2 antibodies.
There have been a lot of reports in which the treatment with
anti-HER2 antibodies for various cancers has resulted in clinical
responses; however, there have been also subsets of cancer patients
who did not respond initially, and several responding patients
developed resistance following treatments. Sections cover
Lapatinib, Ganetespib, Paclitaxel, Celecoxib, Emantasine, Liposomal
Doxorubicin, and Kinase Inhibitors. This book is a valuable source
for cancer researchers, oncologists, pharmacologists and different
members of the biomedical field interested in fighting cancer
resistance to HER-2 antibodies.
General
| Imprint: |
Academic Press Inc
|
| Country of origin: |
United States |
| Series: |
Breaking Tolerance to Antibody-Mediated Immunotherapy |
| Release date: |
September 2023 |
| First published: |
2024 |
| Editors: |
Benjamin Bonavida
|
| Dimensions: |
234 x 191mm (L x W) |
| Format: |
Hardcover
|
| Pages: |
250 |
| ISBN-13: |
978-0-12-816408-2 |
| Categories: |
Books
|
| LSN: |
0-12-816408-5 |
| Barcode: |
9780128164082 |
Is the information for this product incomplete, wrong or inappropriate?
Let us know about it.
Does this product have an incorrect or missing image?
Send us a new image.
Is this product missing categories?
Add more categories.
Review This Product
No reviews yet - be the first to create one!
Welcome to Loot.co.za!
Sign in / Register |Wishlists & Gift Vouchers |Help | Advanced search
(1)
